Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 18663586 | Dynamically Controlled Treatment Protocols for Autonomous Treatment Systems | May 2024 | March 2026 | Allow | 22 | 1 | 0 | No | No |
| 18661355 | SYSTEMS AND METHODS FOR SELECTING AN INTERVENTION BASED ON EFFECTIVE AGE | May 2024 | December 2025 | Allow | 19 | 0 | 0 | No | No |
| 18625510 | METHODS AND SYSTEMS FOR INFORMING PRODUCT DECISIONS | April 2024 | January 2026 | Abandon | 22 | 1 | 0 | No | No |
| 18609451 | CARE PLAN ADMINISTRATION: PATIENT FEEDBACK | March 2024 | April 2025 | Allow | 12 | 0 | 0 | Yes | No |
| 18434170 | DEVICES, SYSTEMS, AND METHODS FOR ADHERENCE MONITORING AND PATIENT INTERACTION | February 2024 | August 2025 | Abandon | 18 | 1 | 0 | No | No |
| 18503014 | Method for Extracting Event Information from Calendar Representations | November 2023 | November 2025 | Abandon | 24 | 1 | 0 | No | No |
| 18491759 | SimPillRx | October 2023 | November 2025 | Abandon | 25 | 1 | 0 | No | No |
| 18489412 | Disease-Specific Semantic Model Instance Generation and Maintenance | October 2023 | September 2025 | Abandon | 23 | 3 | 0 | Yes | No |
| 18484083 | SYSTEMS AND METHODS FOR MEDICATION ADHERENCE | October 2023 | January 2025 | Abandon | 15 | 1 | 0 | No | No |
| 18372362 | APPARATUS AND METHOD FOR DETERMINING RARITY OF BIOMETRIC INFORMATION SIGNAL | September 2023 | December 2025 | Abandon | 27 | 1 | 0 | No | No |
| 18281192 | INFORMATION PROVIDING APPARATUS, INFORMATION PROCESSING METHOD, AND RECORDING MEDIUM | September 2023 | November 2025 | Abandon | 26 | 2 | 0 | No | No |
| 18232231 | DETERMINING LIKELY RESPONSE TO ANTI-INFLAMMATORY AND PRO-RESOLVING THERAPIES FOR CARDIOVASCULAR DISEASE NON-INVASIVELY | August 2023 | May 2024 | Allow | 10 | 0 | 0 | No | No |
| 18232138 | DETERMINING LIKELY RESPONSE TO GLYCEMIC TREATMENT FOR CARDIOVASCULAR DISEASE NON-INVASIVELY | August 2023 | May 2024 | Allow | 10 | 0 | 0 | No | No |
| 18327863 | NIGHT LIGHT WITH EMBEDDED CELLULAR MODEM | June 2023 | June 2025 | Abandon | 25 | 2 | 0 | No | No |
| 18321651 | CAP FOR OPTICAL ILLUMINATION ON A CONTAINER | May 2023 | December 2024 | Allow | 19 | 2 | 0 | Yes | Yes |
| 18199002 | SYSTEMS AND METHODS FOR NODE GRAPH STORAGE FOR STORING PATIENT DATA ACROSS CLINICS | May 2023 | September 2024 | Allow | 16 | 2 | 0 | Yes | No |
| 18132510 | SYSTEM FOR ADMINISTERING A MEDICAMENT | April 2023 | October 2024 | Allow | 18 | 1 | 0 | No | No |
| 18188628 | SYSTEMS AND METHODS FOR MANAGING REGIMEN ADHERENCE | March 2023 | January 2025 | Abandon | 22 | 2 | 0 | Yes | No |
| 18177103 | DENTAL SCANNING SYSTEMS | March 2023 | January 2026 | Abandon | 35 | 4 | 0 | Yes | No |
| 18155724 | System and Method for Screening Potential Test Subjects for Participation in Recent Trials | January 2023 | September 2024 | Allow | 20 | 2 | 0 | No | No |
| 18097086 | ELECTRONIC INTERFACE FOR HEALTHCARE RESOURCE SCHEDULING | January 2023 | September 2024 | Allow | 20 | 3 | 0 | Yes | No |
| 18047518 | REMOTE DIAGNOSTIC TESTING SYSTEMS AND METHODS | October 2022 | September 2025 | Abandon | 35 | 1 | 0 | No | No |
| 17965818 | METHOD FOR DISEASE RISK ASSESSMENT | October 2022 | June 2025 | Abandon | 32 | 1 | 0 | No | No |
| 17962246 | ADAPTIVE SPECIMEN COLLECTION ORDER PROCESSING | October 2022 | June 2025 | Abandon | 33 | 1 | 0 | No | No |
| 17786878 | METHODS AND SYSTEMS FOR DETERMINING OPTIMAL DECISION TIME RELATED TO EMBRYONIC IMPLANTATION | June 2022 | January 2026 | Allow | 43 | 2 | 0 | Yes | No |
| 17478847 | ELECTRICAL BICYCLE ("E-BIKE") DETECTOR FOR ENERGY EXPENDITURE ESTIMATION | September 2021 | July 2025 | Abandon | 46 | 3 | 0 | Yes | No |
| 17397836 | Method for providing wearable device-collected physiological information to relevant service providers | August 2021 | November 2024 | Abandon | 40 | 2 | 0 | No | No |
| 17180292 | CONNECTED FACILITY SYSTEMS | February 2021 | March 2026 | Abandon | 60 | 4 | 0 | No | No |
| 17170030 | UPDATING A PHARMACEUTICAL CONTENT ITEM | February 2021 | November 2025 | Abandon | 58 | 4 | 0 | Yes | No |
| 17143083 | GENERATING EMBEDDINGS OF MEDICAL ENCOUNTER FEATURES USING SELF-ATTENTION NEURAL NETWORKS | January 2021 | April 2025 | Abandon | 51 | 4 | 0 | No | No |
| 17142791 | SYSTEMS AND METHODS FOR AUTOMATED PROCESSING OF MEDICAL PRESCRIPTIONS | January 2021 | February 2026 | Abandon | 60 | 4 | 0 | Yes | No |
| 17127843 | ESTIMATING IMPACT OF PROPERTY ON INDIVIDUAL HEALTH -- COGNITIVE CALCULATOR | December 2020 | December 2024 | Allow | 48 | 2 | 0 | Yes | No |
| 17114262 | SYSTEMS AND METHODS FOR AUTOMATED MEDICAL DIAGNOSTICS | December 2020 | March 2025 | Abandon | 51 | 3 | 0 | No | No |
| 17036671 | INTEGRATED HEALTHCARE METHODS AND SYSTEMS | September 2020 | December 2024 | Allow | 50 | 4 | 0 | Yes | No |
| 16913940 | SENIOR LIVING CARE COORDINATION PLATFORMS | June 2020 | December 2025 | Abandon | 60 | 8 | 0 | Yes | No |
| 16956185 | Portable Medical Memory | June 2020 | October 2025 | Allow | 60 | 6 | 0 | Yes | Yes |
| 16856865 | DIGITAL QUALIMETRIC BIOMARKERS FOR COGNITION AND MOVEMENT DISEASES OR DISORDERS | April 2020 | September 2024 | Allow | 53 | 4 | 0 | Yes | No |
| 16812209 | ANALYSIS AND PRESENTATION OF AGGREGATED PATIENT AND DEVICE DATA WITHIN A SYSTEM THAT INCLUDES A MEDICAL DEVICE | March 2020 | December 2024 | Allow | 57 | 6 | 0 | Yes | No |
| 16619329 | PARAMETER VALUE ESTIMATION IN COAGULATION SYSTEM | December 2019 | January 2026 | Abandon | 60 | 6 | 0 | Yes | No |
| 16589374 | Identification of Clinical Inference Rules | October 2019 | August 2025 | Abandon | 60 | 2 | 0 | No | Yes |
| 16559465 | GENETIC VARIANT DETECTION BASED ON MERGED AND UNMERGED READS | September 2019 | May 2025 | Abandon | 60 | 3 | 0 | No | No |
| 16294702 | GRAPHICAL DISPLAY OF DOSE RATE INFORMATION FOR RADIATION TREATMENT PLANNING | March 2019 | January 2026 | Allow | 60 | 6 | 0 | Yes | Yes |
| 16292877 | SYSTEM AND METHOD FOR REVIEW OF AUTOMATED CLINICAL DOCUMENTATION | March 2019 | August 2025 | Abandon | 60 | 4 | 0 | Yes | Yes |
| 16289450 | SYSTEMS AND METHODS FOR DETERMINING PATIENT HOSPITALIZATION RISK AND TREATING PATIENTS | February 2019 | January 2026 | Allow | 60 | 8 | 0 | Yes | No |
| 16306704 | MEDICAL IMAGE WORKFLOW SYSTEM AND METHOD | December 2018 | September 2021 | Abandon | 33 | 4 | 0 | No | Yes |
| 16103414 | MANAGING PROVIDER ROLES IN MEDICAL CARE | August 2018 | July 2025 | Abandon | 60 | 6 | 0 | Yes | Yes |
| 15794435 | BOTTLE CAP WITH ELECTRONIC EMBEDDED CURVED DISPLAY | October 2017 | December 2024 | Allow | 60 | 7 | 0 | Yes | Yes |
| 15355472 | SYSTEMS AND METHODS FOR GENERATING MEDICAL DIAGNOSIS | November 2016 | January 2025 | Abandon | 60 | 5 | 0 | No | Yes |
| 15352488 | SYSTEMS AND METHODS FOR MEDICAL INSTRUMENT PATIENT MEASUREMENTS | November 2016 | May 2023 | Abandon | 60 | 7 | 0 | Yes | Yes |
| 15347146 | System for Collecting Medical Data Using Proxy Inputs | November 2016 | February 2025 | Abandon | 60 | 7 | 0 | Yes | Yes |
| 15169689 | CONTEXT AND LOCATION SPECIFIC REAL TIME CARE MANAGEMENT SYSTEM | May 2016 | August 2025 | Abandon | 60 | 10 | 0 | Yes | No |
| 15006274 | Medicine ingestion state management method, medicine and medicine ingestion state management device | January 2016 | September 2019 | Allow | 44 | 2 | 0 | Yes | No |
| 14900448 | MULTIDIMENSIONAL TIME SERIES ENTRAINMENT SYSTEM, METHOD AND COMPUTER READABLE MEDIUM | December 2015 | August 2025 | Abandon | 60 | 13 | 0 | No | No |
| 14899764 | ECG FEATURES FOR TYPE AHEAD EDITING AND AUTOMATIC UPDATE FOR REPORT INTERPRETATION | December 2015 | April 2025 | Allow | 60 | 8 | 0 | Yes | Yes |
| 13025617 | EXTENDED WEB ENABLED BUSINESS TO BUSINESS COMPUTER SYSTEM FOR RENTAL VEHICLE SERVICES | February 2011 | November 2012 | Allow | 21 | 1 | 0 | No | No |
| 13025546 | METHOD AND SYSTEM FOR MANAGING RENTAL VEHICLE RESERVATIONS WITH USER AUTHORIZATION LIMITS | February 2011 | June 2012 | Allow | 16 | 0 | 0 | No | No |
| 12964565 | HEALTH-CARE E-COMMERCE SYSTEMS AND METHODS | December 2010 | January 2019 | Allow | 60 | 8 | 0 | Yes | No |
| 12466684 | METHODS AND SYSTEMS FOR INTEGRATED HEALTH SYSTEMS | May 2009 | December 2012 | Allow | 43 | 2 | 0 | Yes | No |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner COLEMAN, CHARLES P..
With a 11.1% reversal rate, the PTAB affirms the examiner's rejections in the vast majority of cases. This reversal rate is in the bottom 25% across the USPTO, indicating that appeals face significant challenges here.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 12.5% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the bottom 25% across the USPTO, indicating that filing appeals is less effective here than in most other areas.
⚠ Appeals to PTAB face challenges. Ensure your case has strong merit before committing to full Board review.
⚠ Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.
Examiner COLEMAN, CHARLES P. works in Art Unit 3683 and has examined 33 patent applications in our dataset. With an allowance rate of 42.4%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 10000 months.
Examiner COLEMAN, CHARLES P.'s allowance rate of 42.4% places them in the 8% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.
On average, applications examined by COLEMAN, CHARLES P. receive 4.94 office actions before reaching final disposition. This places the examiner in the 99% percentile for office actions issued. This examiner issues more office actions than most examiners, which may indicate thorough examination or difficulty in reaching agreement with applicants.
The median time to disposition (half-life) for applications examined by COLEMAN, CHARLES P. is 10000 months. This places the examiner in the 1% percentile for prosecution speed. Applications take longer to reach final disposition with this examiner compared to most others.
Conducting an examiner interview provides a +36.4% benefit to allowance rate for applications examined by COLEMAN, CHARLES P.. This interview benefit is in the 84% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.
When applicants file an RCE with this examiner, 5.7% of applications are subsequently allowed. This success rate is in the 2% percentile among all examiners. Strategic Insight: RCEs show lower effectiveness with this examiner compared to others. Consider whether a continuation application might be more strategic, especially if you need to add new matter or significantly broaden claims.
This examiner enters after-final amendments leading to allowance in 13.9% of cases where such amendments are filed. This entry rate is in the 14% percentile among all examiners. Strategic Recommendation: This examiner rarely enters after-final amendments compared to other examiners. You should generally plan to file an RCE or appeal rather than relying on after-final amendment entry. Per MPEP § 714.12, primary examiners have discretion in entering after-final amendments, and this examiner exercises that discretion conservatively.
When applicants request a pre-appeal conference (PAC) with this examiner, 50.0% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 45% percentile among all examiners. Note: Pre-appeal conferences show below-average success with this examiner. Consider whether your arguments are strong enough to warrant a PAC request.
This examiner withdraws rejections or reopens prosecution in 35.7% of appeals filed. This is in the 6% percentile among all examiners. Of these withdrawals, 20.0% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner rarely withdraws rejections during the appeal process compared to other examiners. If you file an appeal, be prepared to fully prosecute it to a PTAB decision. Per MPEP § 1207, the examiner will prepare an Examiner's Answer maintaining the rejections.
When applicants file petitions regarding this examiner's actions, 120.0% are granted (fully or in part). This grant rate is in the 95% percentile among all examiners. Strategic Note: Petitions are frequently granted regarding this examiner's actions compared to other examiners. Per MPEP § 1002.02(c), various examiner actions are petitionable to the Technology Center Director, including prematureness of final rejection, refusal to enter amendments, and requirement for information. If you believe an examiner action is improper, consider filing a petition.
Examiner's Amendments: This examiner makes examiner's amendments in 0.0% of allowed cases (in the 40% percentile). This examiner makes examiner's amendments less often than average. You may need to make most claim amendments yourself.
Quayle Actions: This examiner issues Ex Parte Quayle actions in 0.0% of allowed cases (in the 43% percentile). This examiner issues Quayle actions less often than average. Allowances may come directly without a separate action for formal matters.
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.